Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Recap by typeshit. Post by Lilly Medical US on X.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
A short teaser comparing how well people tolerate the two main GLP-1 ingredients, with the full breakdown behind the link.
Loading…